Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of voxelotor in sickle cell disease
PACTR202509627939569Phase 3Unknown
- Sponsor
- Global Blood Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics. Primary endpoint: Improvement in anemia. Status: unknown.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202509627939569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509627939569.